Debate over GSK's Avandia rages as FDA gears up for panel meeting
This article was originally published in Scrip
Controversy surrounding GlaxoSmithKline's blockbuster diabetes drug, Avandia (rosiglitazone), has reached fever pitch just days before a US FDA advisory panel review of the drug is set to begin on 13 July. GSK has found itself once again defending against attacks from the FDA's drug safety official Dr David Graham and Dr Steven Nissen of the Cleveland Clinic. Both are staunch Avandia critics, who have just had separate publications in major journals in conjunction with the recent American Diabetes Association (ADA) meeting. Now, US lawmakers are also calling for the FDA to justify its reasons for keeping the drug on the market.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.